Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 2;8(1):66-73.
doi: 10.1080/21505594.2016.1213476. Epub 2016 Jul 18.

Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Affiliations

Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?

Valerio Del Bono et al. Virulence. .

Abstract

The objective of this study was to assess the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets of meropenem (MEM) in critically-ill patients with bloodstream infections (BSI) due to Klebsiella pneumoniae-carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) with MEM minimum inhibitory concentrations (MICs) ≥16 mg/L. Nineteen critically-ill patients with KPC-Kp BSI were given combination therapy including MEM, tigecycline, plus colistin or gentamicin (according to susceptibility testing). MEM was administered as an extended 3-hour infusion of 2 g every 8 hours, or adjusted according to renal function. MEM plasma concentrations were determined by high-performance liquid chromatography. PK/PD targets for MEM were defined as T > 40% 1×MIC and T > 40% 4×MIC. Possible synergisms between MEM and coadministered agents were assessed by time-kill assays based on plasma levels for MEM and on fixed plasma concentrations for the other agents. In none of 19 patients MEM reached any PK/PD target. The actual MEM MICs were 256, 512, and 1024 mg/L in 1, 3, and 15 isolates, respectively. However, theoretically, the PK/PD target of T > 40% 1×MIC could have been achieved in 95%, 68%, 32% and 0% of the isolates for MIC equal to 8, 16, 32, and 64 mg/L, respectively. No synergisms were observed between MEM and coadministered agents. In conclusion, high-dose MEM failed to reach PK/PD targets in 19 patients with BSI due to KPC-Kp with very high MEM MICs. On a theoretical basis, our results suggest a possible usefulness of MEM against resistant blood isolates with MICs up to 32 mg/L.

Keywords: KPC; Klebsiella pneumoniae; PK/PD; bloodstream infections; carbapenemases; meropenem MICs; treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Achievement of T > 40% 1×MIC by measured meropenem levels in 19 critically-ill patients with BSI due to KPC-Kp, according to different hypothetical meropenem MICs. Actual meropenem MICs of all 19 isolates turned out to be far higher than those compatible with the achievement of such a PK/PD target, ranging from 256 to 1024 mg/L.

Comment in

Similar articles

Cited by

References

    1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, et al.. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96; PMID:23969216; http://dx.doi.org/10.1016/S1473-3099(13)70190-7 - DOI - PMC - PubMed
    1. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 2012; 18:263-72; PMID:22480775; http://dx.doi.org/10.1016/j.molmed.2012.03.003 - DOI - PubMed
    1. Hirsch EB, Tam VH. Detection and treatment option for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-25; PMID:20378670; http://dx.doi.org/10.1093/jac/dkq108 - DOI - PubMed
    1. Giacobbe DR, Del Bono V, Marchese A, Viscoli C. Early carbapenem-resistant Klebsiella pneumoniae bacteraemia: should we expand the screening? Clin Microbiol Infect 2014; 20:O1157-O1158; PMID:25366247; http://dx.doi.org/10.1111/1469-0691.12804 - DOI - PubMed
    1. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60-7; PMID:21653305; http://dx.doi.org/10.1093/cid/cir202 - DOI - PubMed

MeSH terms